IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, IdeS is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients (123).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global burden of group A streptococcal diseases
Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70267-x · Cited by 2,998
Significance of the Positive Crossmatch Test in Kidney Transplantation
Patel, R., & Terasaki, P. I. (1969) · New England Journal of Medicine · doi:10.1056/nejm196904032801401 · Cited by 1,508
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350 · cited 1×
“Scoring of various values (complement factor 4d deposition [C4d+], interstitial fibrosis and tubular atrophy [IFTA], glomerulitis plus peritubular capillaritis [GPC], transplant glomerulopathy [TG], and thrombotic microangiopathy [TMA]) was based on Banff 2013 criteria.(18) T bars indicate 1 SD.”
MethodSelf-citationThe Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., van Huyen, J.-P. D., Mooney, N., Suberbielle, C., Frémeaux-Bacchi, V., Méjean, A., Desgrandchamps, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302506 · Cited by 852
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Lefaucheur, C., Loupy, A., Hill, G. S., Andrade, J., Nochy, D., Antoine, C., Gautreau, C., Charron, D., Glotz, D., & Suberbielle-Boissel, C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101065 · Cited by 789
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Self-citationDesensitization in HLA-Incompatible Kidney Recipients and Survival
Montgomery, R. A., Lonze, B. E., King, K. E., Kraus, E. S., Kucirka, L. M., Locke, J. E., Warren, D. S., Simpkins, C. E., Dagher, N. N., Singer, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012376 · Cited by 687
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel-Rammingen, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 473
Research works printed but not linked: 1
- 12. ies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398406.
Cited by
Items 101–200 of 376
Structural insights into the mechanisms and specificities of IgG-active endoglycosidases
Du, J. J., Klontz, E. H., Guerin, M. E., Trastoy, B., & Sundberg, E. J. (2019) · Glycobiology · doi:10.1093/glycob/cwz042 · Cited by 27
“pyogenes, has recently been studied for its therapeutic application in the treatment of thrombotic thrombocytopenic purpura and graft rejection following kidney transplantation, and has passed safety and efficacy trials in humans (Winstedt et al. 2015; Jordan et al. 2017; Lorant et al. 2018; Stubbs et al. 2018).”
BackgroundThe deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Kidney transplantation in highly sensitized recipients
Park, Y., Ko, E. J., Chung, B. H., & Yang, C. W. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.012 · Cited by 31
Preventing Rejection of the Kidney Transplant
Malhotra, D., & Jethwani, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185938 · Cited by 29
“It decreased the DSA levels in patients with AMR after 1 year of transplant and showed a significantly slower decline in GFR as compared to placebo.”
BackgroundInfluentialParsons, R. F., Zahid, A. M., Bumb, S., Decker, H. C., Sullivan, H. C., Lee, F. E.-H., Badell, I. R., Ford, M. L., Larsen, C. P., Pearson, T. C., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15585 · Cited by 25
Contemporary Antibody-Mediated Rejection in Heart Transplantation
Mehta, A., DeFilippis, E. M., Stehlik, J., Jackson, A. M., KOBASHIGAWA, J. A., & Shah, P. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102614 · Cited by 24
Determination of unacceptable HLA antigen mismatches in kidney transplant recipients
Ziemann, M., Suwelack, B. M., Banas, B., Budde, K., Einecke, G., Hauser, I., Heinemann, F. M., Kauke, T., Kelsch, R., Koch, M., et al. (2021) · HLA · doi:10.1111/tan.14521 · Cited by 24
Lima, A. C. M., Getz, J., do Amaral, G. B., Loth, G., Funke, V. A. M., Nabhan, S. K., Petterle, R. R., de Marco, R., Gerbase‐DeLima, M., Pereira, N. F., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.05.014 · Cited by 24
Halleck, F., Böhmig, G. A., Couzi, L., Rostaing, L. P. E., Einecke, G., Lefaucheur, C., Legendre, C. M., Montgomery, R. A., Hughes, P., Chandraker, A. K., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15383 · Cited by 23
Self-citationXie, X., Li, J., Liu, P., Wang, M., Gao, L., Wan, F., Lv, J., Zhang, H., & Jin, J. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021030372 · Cited by 24
Lima, A. C. M., Bonfim, C., Getz, J., do Amaral, G. B., Petterle, R. R., Loth, G., Nabhan, S. K., de Marco, R., Gerbase‐DeLima, M., Pereira, N. F., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.019 · Cited by 22
Desensitization strategies: is it worth it?
Kuppachi, S. C., & Axelrod, D. A. (2019) · Transplant International · doi:10.1111/tri.13532 · Cited by 22
Imlifidase-generated Single-cleaved IgG: Implications for Transplantation
Bockermann, R., Järnum, S., Runström, A., Lorant, T., Winstedt, L., Palmqvist, N., & Kjellman, C. (2021) · Transplantation · doi:10.1097/tp.0000000000004031 · Cited by 22
Self-citationMüller, L., Dabbiru, V. A. S., Schönborn, L., & Greinacher, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2328241 · Cited by 33
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 23
Stubbs, M. J., Thomas, M. R., Vendramin, C., Sonesson, E., Kjellman, C., Järnum, S., Stenberg, Y., Elfving, C., & Scully, M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15706 · Cited by 21
“A phase II study of IdeS in CKD patients with anti-HLA antibodies demonstrated reduction/eradication of HLA antibodies permitting HLA-incompatible transplantation in 24/25 patients (Jordan et al, 2017).”
BackgroundSelf-citationImplications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics
Jordan, S. C., Ammerman, N., & Vo, A. A. (2019) · Transplantation · doi:10.1097/tp.0000000000002912 · Cited by 22
“Anti-CD20 monoclonal antibodies (mAbs), typically rituximab or obinutuzumab, are used to prevent rebound DSA development.(3) Despite successes, these treatments are not always effective and can be associated with adverse events, infectious complications, and high cost.”
BackgroundSelf-citationGuest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 25
Imlifidase Desensitization in HLA-incompatible Kidney Transplantation: Finding the Sweet Spot
de Weerd, A. E., Roelen, D. L., van de Wetering, J., Betjes, M. G. H., Heidt, S., & Reinders, M. E. J. (2023) · Transplantation · doi:10.1097/tp.0000000000004689 · Cited by 20
“Jordan et al described 19 flow cytometric crossmatch-positive patients (immunodominant DSA of MFI >20 000 in 7, >10 000 in 3, and 10 000 in 9 patients).”
BackgroundMethodInfluentialLeal, R. G. C., Pardinhas, C., Martinho, A., Sá, H. O., Figueiredo, A., & Alves, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195753 · Cited by 20
Hulbert, A. L., Pavlisko, E. N., & Palmer, S. M. (2018) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000537 · Cited by 20
Peraro, L., Bourne, C. M., Dacek, M. M., Akalin, E., Park, J. H., Smith, E. L., & Scheinberg, D. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.022 · Cited by 20
Recommendations for living donor kidney transplantation
Frutos, M. Á., Crespo, M., Valentín, M. D. L. O., Melgar, Á. A., Alonso, J., Fernández, C., Erauzkin, G. G., González, E., González-Rinne, A. M., Guirado, L., et al. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.07.001 · Cited by 24
Bhargava, R., Maeda, K., Tsokos, M., Pavlakis, M., Stillman, I. E., & Tsokos, G. C. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16140 · Cited by 19
Manook, M., Flores, W. J., Schmitz, R., Fitch, Z. W., Yoon, J., Bae, Y., Shaw, B. I., Kirk, A. D., Harnois, M. J., Permar, S. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660900 · Cited by 19
“In the clinical setting of HLA-incompatible transplantation, the introduction of IdeS (imlifidase) has permitted highly sensitized patients to receive a deceased donor kidney against whom they have a positive initial crossmatch by cleaving soluble IgG at the lower hinge region, thus generating F(ab) and Fc fragments a…”
BackgroundApproaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells
Matsuda, Y., Watanabe, T., & Li, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682334 · Cited by 19
“antibody-producing cells Reduction of anti-HLA antibodies level (121, 122)”
BackgroundInvestigational drugs for the treatment of kidney transplant rejection
van Vugt, L. K., Schagen, M. R., de Weerd, A., Reinders, M. E. J., de Winter, B. C. M., & Hesselink, D. A. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2130751 · Cited by 20
On a Long and Winding Road: Alloantibodies in Organ Transplantation
Böhmig, G. A., Halloran, P. F., & Feucht, H. E. (2023) · Transplantation · doi:10.1097/tp.0000000000004550 · Cited by 21
Xenogeneic cross-circulation for physiological support and recovery of ex vivo human livers
Wu, W. K., Ukita, R., Patel, Y. J., Cortelli, M., Trinh, V. Q., Ziogas, I. A., Francois, S. A., Mentz, M., Cardwell, N. L., Talackine, J. R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000357 · Cited by 18
Imlifidase in kidney transplantation
Kanbay, M., Çöpür, S., Güldan, M., Topçu, A. U., Özbek, L., Hasbal, N. B., Süsal, C., Koçak, B., Callemeyn, J., & Segelmark, M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae033 · Cited by 19
Mehra, M. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)33093-3 · Cited by 18
Rethinking clinical endpoints in kidney transplant trials
Maggiore, U., Leventhal, J. S., & Cravedi, P. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000719 · Cited by 20
“Other examples of the use of DSA as endpoints are RCT on the treatment of antibody-mediated rejection [40,41], where trial drugs effect DSA titer per se [42].”
BackgroundAdvancing immunosuppression in liver transplantation: A narrative review
Iesari, S., Nava, F. L., Zais, I. E., Coubeau, L., Ferraresso, M., Favi, E., & Lerut, J. P. (2024) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2024.03.001 · Cited by 18
Developments in immunosuppression
Viklický, O., Slatinská, J., Novotny, M., & Hrubá, P. (2020) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000844 · Cited by 17
Advances in the immunology of heart transplantation
Madsen, J. C. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.10.003 · Cited by 17
Kamar, N., Bertrand, D., Caillard, S., Pievani, D., Apithy, M.-J., Congy‐Jolivet, N., Chauveau, B., Farce, F., François, A., Delas, A., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.07.024 · Cited by 17
Léon, J., Aubert, O., Devriese, M., Alameda, F., Charbonnier, S., Fourgeaud, J., Blein, T., Nguyễn, T. N., Troger, A., Chhun, S., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.01.020 · Cited by 19
Kervella, D., Bas‐Bernardet, S. L., Bruneau, S., & Blancho, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932242 · Cited by 18
“Frontiers in Immunology 16 Streptococcus pyogenes (IdeS), cleaving human IgG intro F (ab’)2 and Fc fragments and thus inhibiting CDC and ADCC of DSA, could be beneficial for accommodation induction (87).”
BackgroundMethodInfluentialFrick, I.-M., Happonen, L., Wrighton, S., Nordenfelt, P., & Björck, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105345 · Cited by 16
“However, treatment with IdeS eliminated these antibodies and permitted successful transplantation in 24 of 25 such patients (37), and the effect of IdeS in other IgG-driven diseases is currently under investigation.”
BackgroundNew Therapies for Highly Sensitized Patients on the Waiting List
Vo, A. A., Ammerman, N., & Jordan, S. C. (2024) · Kidney360 · doi:10.34067/kid.0000000000000509 · Cited by 18
Self-citationMessika, J., Belousova, N., Parquin, F., & Roux, A. (2024) · Transplant International · doi:10.3389/ti.2024.12973 · Cited by 18
Desensitization in heart transplant recipients: Who, when, and how
Shah, K., & Patel, J. K. (2019) · Clinical Transplantation · doi:10.1111/ctr.13639 · Cited by 16
Roux, A., Bunel, V., Belousova, N., Messika, J., Tanaka, S., Salpin, M., Roussel, A., Beaumont, L., Picard, C., Brugière, O., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.11.025 · Cited by 16
Experimental modeling of desensitization: What have we learned about preventing AMR?
Kwun, J., & Knechtle, S. J. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15873 · Cited by 16
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
“Treatment with Imlifidase, an endopeptidase used in transplanted patients [130] that degrades circulating IgG,”
Velleca, A., Shullo, M. A., Dhital, K. K., Azeka, E., Colvin, M. M., DePasquale, E. C., Farrero, M., García-Guereta, L., Jamero, G., Khush, K. K., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.023 · Cited by 19
RetractedEnzymolysis-based RNA pull-down identifies YTHDC2 as an inhibitor of antiviral innate response
Zhu, J., Liu, S., Fang, J., Cui, Z., Wang, B., Wang, Y., Liu, L., Wang, Q., & Cao, X. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113192 · Cited by 17
Novel strategies to target the humoral alloimmune response
Suchánek, O., & Clatworthy, M. R. (2020) · HLA · doi:10.1111/tan.14092 · Cited by 17
“Two openlabel phase 1/2 trials (in US and Sweden) reported successful HLA-incompatible kidney transplantation in 24 of 25 patients 4 to 6 hours after IdeS administration.(143) In contrast to the Swedish group, the US patient cohort received IVIG plus rituximab 7 to 14 days after transplant, which prevented DSA rebound.”
BackgroundTargeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues
Nandakumar, K. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030677 · Cited by 15
Novel Approaches to Block Complement
Böhmig, G. A., Wahrmann, M., Eskandary, F. A., & Rostaing, L. P. E. (2018) · Transplantation · doi:10.1097/tp.0000000000002267 · Cited by 15
Advances in desensitization for human leukocyte antigen incompatible kidney transplantation
Vo, A. A., Ammerman, N., & Jordan, S. C. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001131 · Cited by 15
Self-citationEnzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy
Järnum, S., Runström, A., Bockermann, R., Winstedt, L., Crispin, M., & Kjellman, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0108 · Cited by 15
Self-citationABO‐incompatible living kidney transplantation
Cen, M., Wang, R., Kong, W., Deng, H., Lei, W., & Chen, J. (2020) · Clinical Transplantation · doi:10.1111/ctr.14050 · Cited by 14
APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice
Wilson, N. A., Bath, N. M., Verhoven, B. M., Ding, X., Boldt, B. A., Sukhwal, A., Zhong, W., Panzer, S. E., & Redfield, R. R. (2019) · Transplantation · doi:10.1097/tp.0000000000002686 · Cited by 14
Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi, P., Jouvé, T., Noble, J., & Rostaing, L. P. E. (2018) · Experimental and Clinical Transplantation · doi:10.6002/ect.2017.0355 · Cited by 14
DeLaura, I. F., Zikos, J., Anwar, I. J., Yoon, J., Ladowski, J. M., Jackson, A. M., Rompay, K. K. A. V., Magnani, D. M., Knechtle, S. J., & Kwun, J. (2023) · Xenotransplantation · doi:10.1111/xen.12833 · Cited by 13
Modern advances in heart transplantation
Srivastava, P. K., & Kittleson, M. M. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.012 · Cited by 13
New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy
Dang, S., Zhang, X., Zhang, Y., & Zhang, H. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103835 · Cited by 15
Self-citationDesensitization in the Era of Precision Medicine: Moving From the Bench to Bedside
Habal, M. V., FARR, M. A., Restaino, S. W., & Chong, A. S. (2019) · Transplantation · doi:10.1097/tp.0000000000002737 · Cited by 13
Novel insights in the clinical management of hyperimmune patients before and after transplantation
Grimaldi, V., Pagano, M., Moccia, G., Maiello, C., Rosa, P. D., & Claudio Napoli, A. (2023) · Current Research in Immunology · doi:10.1016/j.crimmu.2023.100056 · Cited by 13
Hahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
Segelmark, M., & Björck, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02165 · Cited by 13
“A single dose given prior to transplantation enabled transplantations in 24 out 25 such sensitized patients who if they ultimately receive a kidney at all, may have to wait for years for a matching kidney (35).”
BackgroundBayer, A. C., Sanmarco, L. M., Pellerin, A., Masi, G., Plasencia, A., Anderson, J. M., Nowak, R. J., Damato, V., Massacesi, L., Pham, M. C., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505984122 · Cited by 12
Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them
Ravichandran, A. J., Romeo, F. J., Mazurek, R., & Ishikawa, K. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.02.011 · Cited by 12
Emerging immunotherapies for autoimmune kidney disease
Foster, M. H., & Ord, J. R. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1555569 · Cited by 14
“Its activity in a clinical setting was recently demonstrated in open-label phase 1–2 trials in which IdeS administered to highly HLA-sensitized patients rapidly abolished total and donor-specific anti-HLA IgG and permitted HLA-incompatible kidney transplantation.(66) IdeS thus presents”
BackgroundImlifidase therapy: exploring its clinical uses
Rostaing, L. P. E., Noble, J., Malvezzi, P., & Jouvé, T. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2150965 · Cited by 12
The regulatory roles of B cell subsets in transplantation
Chu, Z., Zou, W., Xu, Y., Sun, Q., & Zhao, Y. X. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1426461 · Cited by 15
Huang, E., & Jordan, S. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12031017 · Cited by 12
Self-citationMancebo, E., Diekmann, F., Palou, E., Vilches, C., Crespo, M., Mazuecos, A., Caro, J. L., Cruzado, J. M., Segundo, D. S., Muro, M., et al. (2025) · Transplantation Reviews · doi:10.1016/j.trre.2025.100919 · Cited by 11
Novel therapies for treatment of antibody-mediated rejection of the kidney
Sethi, S., & Jordan, S. C. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001037 · Cited by 11
“We first reported the combined experience of two independently performed open-label phase 1/2 trials of imlifidase for desensitization from Sweden and the United States [24].”
BackgroundSelf-citationBertacchi, M., Parvex, P., & Villard, J. (2022) · Clinical Transplantation · doi:10.1111/ctr.14608 · Cited by 11
Humoral Alloreactivity in VCA Recipients: Should We Learn From Our Experience?
Sicard, A., Kanitakis, J., Dubois, V., Morélon, E., & Thaunat, O. (2020) · Transplantation · doi:10.1097/tp.0000000000003164 · Cited by 12
Geoghegan, L., Al-Khalil, M., Scarborough, A., Murray, A., & Issa, F. (2020) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2020.05.010 · Cited by 12
Ni, B., Yang, C., Zhang, J., Zhou, H., Zheng, M., Feng, D., Shen, Q., Miao, J., Sun, X., Sun, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202417119 · Cited by 11
Iroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
New immunosuppressive agents in transplantation
Kervella, D., & Blancho, G. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104142 · Cited by 11
Assessment and management of allosensitization following heart transplant in adults
Jaiswal, A., Bell, J., DeFilippis, E. M., Kransdorf, E. P., Patel, J. K., KOBASHIGAWA, J. A., Kittleson, M. M., & Baran, D. A. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.12.011 · Cited by 10
Conventional and Novel Approaches to Immunosuppression in Lung Transplantation
Patterson, C. M., Jolly, E. C., Burrows, F. S., Ronan, N. J., & Lyster, H. S. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.009 · Cited by 11
Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders
Wang, J., Gao, G., & Wang, D. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00391 · Cited by 10
IgG Degrading Enzyme of Streptococcus Pyogenes
Montgomery, R. A., Lonze, B. E., & Tatapudi, V. (2017) · Transplantation · doi:10.1097/tp.0000000000002003 · Cited by 10
Seeking Standardized Definitions for HLA-incompatible Kidney Transplants: A Systematic Review
Jatana, S., Zhao, H., Bow, L. M., Cozzi, E., Batal, I., Horak, T. E., Amar‐Zifkin, A., Schinstock, C. A., Askar, M. Z., Dadhania, D. M., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004262 · Cited by 11
“The full-text review was undertaken for 886 eligible articles; of these 78 articles discussed HLA incompatibility at the level of the antigen mismatch only,(64-141) whereas 163 articles assessed incompatibility by molecular genotyping, molecular mismatch analysis, and/or pretransplant DSA verification by solid-phase a…”
BackgroundBou-Jaoudeh, M., Delignat, S., Daventure, V., Astermark, J., Levesque, H., Dimitrov, J. D., Deligne, C., Proulle, V., & Lacroix‐Desmazes, S. (2023) · Haematologica · doi:10.3324/haematol.2022.281895 · Cited by 11
Xenotransplantation tolerance: applications for recent advances in modified swine
Llore, N. P., Bruestle, K., & Griesemer, A. (2018) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000585 · Cited by 10
Lin, J., Boon, L., Bockermann, R., Robertson, A.-K., Kjellman, C., & Anderson, C. C. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15851 · Cited by 10
Self-citationLek, A., Atas, E., Lin, B. L., Hesterlee, S. E., Abbott, J. K., Byrne, B. J., & Bönnemann, C. G. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-240002 · Cited by 10
Half‐Life Extension of the IgG‐Degrading Enzyme (IdeS) Using Fc‐Fusion Technology
Daventure, V., Bou-Jaoudeh, M., Hannachi, E., Reyes‐Ruiz, A., Trecco, A., Delignat, S., Lacroix‐Desmazes, S., & Deligne, C. (2024) · European Journal of Immunology · doi:10.1002/eji.202451264 · Cited by 9
Gene Editing: An Effective Tool for the Future Treatment of Kidney Disease
Cao, M., Han, R.-Y., Chen, S.-D., Zhao, D., Shi, M., Zou, J.-H., Li, L., & Jiang, H.-K. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s506760 · Cited by 9
Kuypers, D. R. J., Claas, F. H. J., Bouquegneau, A., Buémi, A., de Fijter, J. W., Emonds, M., Gambino, G., Gervais, T., Gothot, A., Holovská, V., et al. (2025) · Transplantation · doi:10.1097/tp.0000000000005388 · Cited by 9
Chronic rejection models for vascularized composite tissue allotransplantation
Fisher, D. T., Mackey, E. E., Kononov, E., Bogner, P. N., Sharma, U. C., Yu, H., Cetrulo, C. L., Seshadri, M., Kaliński, P., Skitzki, J. J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01803-8 · Cited by 9
Dudreuilh, C., Jarvis, P., Beadle, N., Pilecka, I., Shaw, O., Gardner, L. M., Scottà, C., Mamode, N., Game, D. S., Fueyo, A. S., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03157-7 · Cited by 9
New Perspectives on Desensitization in the Current Era - An Overview
Kumar, V., & Locke, J. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696467 · Cited by 9
“The efficacy of Imlifidase as a desensitization strategy was evaluated in two independent phase I/II trials (12).”
MethodJaffe, I. S., Runström, A., Tatapudi, V., Weldon, E. P., Deterville, C. L., Dieter, R. A., Montgomery, R. A., Lonze, B. E., & Mangiola, M. (2025) · Transplantation Direct · doi:10.1097/txd.0000000000001752 · Cited by 8
“13,14 Imlifidase has been conditionally approved by the European Medicines Agency 17 ; however, the drug remains investigational in the United States.”
Nonclinical strategies and considerations to enable the redosing of gene therapies
Moffit, J. S., Alatsis, K. R., Blanset, D. L., Buss, N. A. P. S., & Rana, P. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101520 · Cited by 10
Milhès, J., Marion, O., Puissant‐Lubrano, B., Carlé, C., Bouthemy, C., Bello, A. D., Kamar, N., Renaudineau, Y., & Congy‐Jolivet, N. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100223 · Cited by 8
“In the phase II clinical study published by Jordan et al. [10,11], the use of imlifidase in highly sensitized patients benefiting from kidney transplantation leads after 6 h to anti-HLA Abs depletion, and after transplantation the graft survival rate reached 89 % with Ab-mediated rejection (ABMR)…”
BackgroundMay, F., Rees, M. T., Griffin, S., & Fildes, J. E. (2021) · Transplantation Reviews · doi:10.1016/j.trre.2021.100596 · Cited by 10
Hiramitsu, T., Tomosugi, T., Futamura, K., Okada, M., Nishihira, M., Goto, N., Ichimori, T., Narumi, S., Kobayashi, T., Uchida, K., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107038 · Cited by 7
Comins‐Boo, A., Irure‐Ventura, J., Valentín, M. O., Belmar, L., del Moral, C. L., Valero, R., Calabia, E. R., Renuncio‐García, M., Castro‐Hernández, C., Mikhalkovich, D., et al. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110806 · Cited by 7
Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion
Speer, C., Kälble, F., da Silva, L. P., Nußhag, C., Schaier, M., Becker, L. E., Klein, K., Beimler, J., Sommerer, C., Leo, A., et al. (2019) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2019.08.030 · Cited by 7
Mazepa, M. A., Park, Y. A., & Raval, J. S. (2019) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2019.06.005 · Cited by 7
Fernando, S., Polkinghorne, K. R., Lim, W. H., & Mulley, W. R. (2023) · Transplantation · doi:10.1097/tp.0000000000004700 · Cited by 8
Metadata
- Authors
- Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., Ge, S., Peng, A., Järnum, S., Wood, K. J., Lundgren, T., Wennberg, L., Bäckman, L., Larsson, E., Villicana, R., Kahwaji, J., Louie, S., Kang, A., Haas, M., Nast, C., Vo, A., & Tufveson, G.
- Affiliations
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-03
- Volume
- 377
- Issue
- 5
- Pages
- 442-453
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2740266422
- Cited by
- 377
- References
- 30
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 37 · 2023: 50 · 2022: 45 · 2021: 39 · 2020: 38 · 2019: 45 · 2018: 36 · 2017: 11
- FWCI
- 30.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- ide, HLA sensitization, kidney transplantation, desensitization, donor-specific antibodies, antibody-mediated rejection, cold ischemia time, delayed graft function, adverse events, antibody rebound
- MeSH terms
- Adult, Antibodies, Bacterial Proteins, Cysteine Endopeptidases, Female, Histocompatibility Testing, HLA Antigens, Humans, Immunoglobulin G, Immunosuppression Therapy, Male, Middle Aged, Transplantation Immunology, Complement C1q, Kidney Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.